Delayed release, oral dosage compositions that contain amorphous cddo-me
AssigneeReata Pharmaceuticals, Inc.
InventorsJiang Zhang, Colin J. MEYER
Life of this patent
Estimating the term…
Abstract
Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based on the crystalline form of bardoxolone methyl.
Claims18
A solid dosage form comprising (A) particles comprised of amorphous bardoxolone methyl admixed with (B) particles comprised of at least one hydrophilic binder, wherein said particles (A) constitute a therapeutically effective amount of bardoxolone methyl.
Dependencies are inferred from the claim text.